Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

(2013) Dan Stark et al.   LANCET ONCOLOGY

Latest research and treatment of advanced-stage epithelial ovarian cancer

(2013) Robert L. Coleman et al.   Nature Reviews Clinical Oncology

How to approach patients in relapse

(2012) E. Pujade-Lauraine   ANNALS OF ONCOLOGY

Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer

(2012) Bradley J. Monk et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

(2012) Georgia A. McCann et al.   GYNECOLOGIC ONCOLOGY

Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study

(2012) Dana M. Chase et al.   GYNECOLOGIC ONCOLOGY

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study

(2012) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF Inhibition, Hypertension, and Renal Toxicity

(2012) Suzanne R. Hayman et al.   Current Oncology Reports

At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis

(2011) David E. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

(2010) Ernest S. Han et al.   GYNECOLOGIC ONCOLOGY

Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model

(2008) S. Mabuchi et al.   CLINICAL CANCER RESEARCH